# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Higuchi Ichiyō (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI029-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Aiko Lindgren-Tanaka, MD
- Calendar frame: modern shifted

## What we are working on

- She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosis **S**
- She supports her household by writing and cannot afford to stop working or to pay for many tests **S**
- She is afraid of passing the illness to the people she lives with and of what neighbors and editors will think **S**

## Your goals

- Complete 182 daily doses within about six and a half months by video-observed therapy. Target: 2026-10-20. Recorded outcome: All 182 doses completed in 26 weeks: 56 in the intensive phase and 126 in the continuation phase, none missed. **S**
- Sputum culture negative at two months. Target: 2026-10-20. Recorded outcome: The cultures taken at two weeks and at two months both showed no growth after six weeks. **S**
- Weight at least 44 kg (BMI about 20) by the end of treatment. Target: 2026-10-20. Recorded outcome: 44.0 kg at the end of treatment, from 38.5 kg at intake. **S**
- Keep writing on a paced schedule without losing income during treatment. Target: 2026-10-20. Recorded outcome: Public funding covered most treatment costs; she kept writing about two hours a day and finished new work. **S**
- No drug-induced liver injury or loss of vision during treatment. Target: 2026-10-20. Recorded outcome: Liver tests normal throughout; visual acuity unchanged. **S**

## What we agreed to do

- Diagnosis and safety: chest X-ray; three sputum specimens at least eight hours apart, one early in the morning, for acid-fast smear, Xpert MTB/RIF Ultra, liquid and solid culture and drug susceptibility testing; HIV, hepatitis B and hepatitis C tests and a pregnancy test; blood count, liver and kidney tests, glucose and hemoglobin A1c; visual acuity and color vision before ethambutol. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017) **S**
- Infectious diseases consultation at the results visit to confirm the diagnosis, choose between the six-month and four-month regimens, set the doses for her weight, and plan monitoring and infection control. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022) **S**
- Infection control and public health: airborne precautions in the clinic; at home, no visitors, a surgical mask in shared rooms, windows open, and sleeping in her own room until the public health center confirms she is no longer infectious; report of suspected tuberculosis to the public health center the same day and notification at once on diagnosis; a contact investigation of her household and other close contacts led by the public health center. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current) **S**
- Nutrition, income and writing: two dietitian visits in the first month, three meals and two energy-dense snacks a day with two oral nutrition supplement drinks, and weight at every visit; a medical social worker to apply for public funding of tuberculosis treatment and to review other help with costs; a paced writing plan of short sessions in daylight with rest; PHQ-9 at intake, at two months and at the end of treatment. Guideline: 結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law) (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Treatment: isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg and ethambutol 600 mg daily for eight weeks, then isoniazid and rifampin daily for eighteen weeks, with pyridoxine 50 mg, by daily video-observed therapy with the public health center; ethambutol stopped once the isolate is susceptible to isoniazid and rifampin; liver tests at two weeks and monthly in the intensive phase because of her low weight and albumin; visual acuity and color vision monthly while on ethambutol; sputum smear and culture at two weeks and two months; chest X-ray at the end of treatment. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006) **S**
- Acute cystitis: nitrofurantoin 100 mg twice daily for five days with urine culture; no fluoroquinolone, because these drugs are kept for drug-resistant tuberculosis and can blur the picture of tuberculosis; continue every tuberculosis dose; plenty of fluids; return for fever, flank pain, vomiting or symptoms that are not better in two days. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases (2010) **S**
- Prevention: cervical cytology now and every three years; Tdap; hepatitis B vaccine in two doses and HPV vaccine in three doses; influenza vaccine in the autumn; folic acid 0.4 mg daily advised; contraception counseling that rifampin makes hormonal pills, patches, rings and implants unreliable, with a copper IUD, injectable progestin or condoms as reliable choices if she needs contraception during treatment. Guideline: Cervical Cancer: Screening (2018); Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication (2023); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); Adult Immunization Schedule by Age (2026) **S**

## Follow-up

- 2026-04-14: New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health center **S**
- 2026-04-17: Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the standard six-month regimen **S**
- 2026-05-01: Two-week review on treatment: culture result, liver tests, vision, and release from precautions **S**
- 2026-06-12: End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase **S**
- 2026-08-24: Periodic adult preventive visit **S**
- 2026-10-20: End-of-treatment review after 182 doses **S**

This teaching document does not replace care from a qualified clinician.
